Skip to content

Can Immunotherapy Cause Itching? A Detailed Guide

4 min read

Around 30% to 40% of patients receiving immunotherapy will experience some form of dermatologic side effect, with itching being one of the most common. This article explores why immunotherapy can cause itching, how to manage the discomfort, and when to consult a healthcare professional.

Quick Summary

Itching, or pruritus, is a frequent side effect of immunotherapy, particularly with immune checkpoint inhibitors, caused by the heightened immune response affecting the skin.

Key Points

  • Common Side Effect: Itching (pruritus) is one of the most common dermatologic side effects of immunotherapy, occurring in up to 40% of patients.

  • Immune System Activation: The itching is caused by the immunotherapy over-activating the immune system, leading to inflammation that affects healthy skin cells.

  • Timing Varies: Itching can begin within weeks of starting treatment, but can also appear much later, sometimes years after completion.

  • Not Always a Rash: The itching can occur with or without a visible rash, and severity ranges from mild to severe.

  • Diverse Treatments: Management includes emollients, oral antihistamines, topical or oral corticosteroids, and in refractory cases, newer agents like gabapentin or aprepitant.

  • Communication is Key: Patients should report all symptoms to their healthcare team for appropriate grading and treatment planning to ensure patient comfort and safety.

  • Potential Positive Indicator: For some, skin reactions may signify that the immune system is actively engaged, though this should not negate the need for symptom management.

In This Article

Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight cancer cells. While effective, this powerful approach can also lead to a range of side effects, known as immune-related adverse events (irAEs). Among the most common are dermatologic reactions, with itching, or pruritus, standing out as a frequent and sometimes distressing symptom. This guide delves into the mechanisms behind immunotherapy-induced itching and outlines effective strategies for its management.

Why Does Immunotherapy Cause Itching?

The primary reason for itching and other skin-related side effects is the over-activation of the immune system. Immunotherapies, especially immune checkpoint inhibitors (ICIs), essentially "take the brakes off" immune cells, primarily T-cells, enabling them to better recognize and attack cancer. However, this heightened immune activity can sometimes be misdirected, causing T-cells to attack healthy cells and tissues in organs like the skin. This misguided attack leads to inflammation, which manifests as a rash, dryness (xerosis), and/or itching.

The Role of Skin Microbiota

Emerging research also suggests a link between the skin's microbial environment (microbiota) and these side effects. A 2022 study in mice found that immune checkpoint inhibitors might cause the immune system to attack new microbes settling on the skin. The resulting inflammation, driven by T-cells producing pro-inflammatory substances, could contribute to the itching and rash. If this is confirmed in human studies, it could lead to new ways of preventing or treating these skin complications.

Other Contributing Factors

  • Type of Immunotherapy: The incidence and severity of itching can vary depending on the specific type of immunotherapy. For instance, combination therapy with ipilimumab and nivolumab has a higher reported incidence of pruritus than single-agent therapies.
  • Individual Susceptibility: Patients with pre-existing inflammatory skin conditions may be more prone to exacerbated dermatologic side effects.
  • Location and Overall Health: The type and location of cancer, as well as the patient's general health, can influence side effects.

Timeline and Characteristics of Immunotherapy Itching

Dermatologic adverse events, including itching, often appear within the first few weeks to months of starting immunotherapy, although they can occur at any point during or even after treatment. The characteristics can vary widely:

  • Generalized Itching: Many patients experience generalized itching (pruritus) with no visible rash.
  • Maculopapular Rash: The most common skin reaction is a maculopapular rash, characterized by flat and raised red areas on the skin.
  • Location: Rashes often appear on the trunk, arms, or legs.
  • Severity: Symptoms are typically mild to moderate, but can sometimes become severe and persistent, impacting a patient's quality of life.

Management and Treatment of Immunotherapy-Induced Itching

Managing pruritus from immunotherapy requires a tailored approach, with the goal of maintaining patient comfort and ensuring treatment compliance. It is crucial for patients to communicate any skin changes to their healthcare team early.

General Skin Care and Lifestyle Adjustments

  • Use lukewarm water for bathing and showering, and avoid harsh soaps.
  • Apply non-perfumed, thick moisturizers or emollients liberally and often, especially after bathing.
  • Wear loose, breathable clothing, preferably cotton.
  • Avoid known skin irritants and excessive sun exposure.

Medical Interventions

Based on the severity, a healthcare provider may recommend one or more of the following:

  • Topical Corticosteroids: For mild to moderate itching, topical steroid creams of varying potency can reduce inflammation.
  • Oral Antihistamines: Over-the-counter or prescription-strength antihistamines, like diphenhydramine, can help relieve itching.
  • Oral Steroids: For severe itching or widespread rash, oral corticosteroids (e.g., prednisone) may be necessary, often requiring a temporary hold or adjustment of the immunotherapy dose.
  • Neuromodulators: For refractory or persistent itching, gamma-aminobutyric acid (GABA) agonists like gabapentin have shown benefit. Aprepitant, a neurokinin 1 receptor agonist, has also been used for severe, refractory pruritus.
  • Biologic Agents: In rare, difficult-to-treat cases, biologic agents like omalizumab or dupilumab may be considered.

Comparison of Itching Severity and Treatment

Feature Mild Itching (Grade 1-2) Severe Itching (Grade 3+)
Appearance May occur with or without a rash; discomfort is manageable. Can be intense, widespread, or disruptive to daily life.
Treatment Options Emollients, oral antihistamines, mild- to high-potency topical corticosteroids. Requires systemic steroids, consideration of neuromodulators, or biologics.
Immunotherapy Status Typically, treatment can be continued with close monitoring. Temporary discontinuation or dose adjustment of immunotherapy may be needed.
Referral Follow-up with oncology team. Urgent dermatology consultation is often recommended.

The “Working” Theory: A Potential Positive Sign?

In some instances, the appearance of skin-related side effects, including itching, can be a positive sign that the immune system is being stimulated effectively to fight the cancer. While this is not a universal rule and should not deter seeking treatment for discomfort, it highlights the immune-activating nature of these therapies. The focus should always be on managing side effects to ensure the best quality of life and adherence to treatment.

Conclusion

In summary, it is well-established that immunotherapy can cause itching, and it is one of the most frequently reported skin-related side effects. The underlying cause is the potent and sometimes overactive immune response triggered by the treatment. By understanding the symptoms, communicating with the healthcare team, and utilizing appropriate management strategies—ranging from simple topical treatments to more advanced systemic medications—patients can effectively address this discomfort. Research continues to uncover the precise mechanisms behind these side effects, which may lead to even better preventive measures in the future, as discussed by the National Cancer Institute.

Frequently Asked Questions

Yes, it is common to experience itching after an immunotherapy infusion. This can be part of an infusion-related reaction or may develop days or weeks later as the immune system becomes more activated.

For mild itching, over-the-counter oral antihistamines like diphenhydramine or topical corticosteroid creams may be recommended. For more severe cases, your doctor may prescribe stronger oral steroids or other agents. Always consult your healthcare team before starting any new medication.

The duration of itching can vary significantly among patients. Some people experience short-term side effects, while others may have persistent or chronic symptoms that require ongoing management.

No, you should not stop immunotherapy without consulting your doctor. While severe itching can be uncomfortable, management strategies are available. Your oncologist and possibly a dermatologist will work with you to manage the side effect, and the treatment may only be temporarily held if the reaction is severe.

Immunotherapy can cause both itching with a visible rash (such as a maculopapular rash) and generalized itching without any apparent rash. The management approaches for both may be similar, but a visible rash may help in grading the severity of the reaction.

Yes, dry skin (xerosis) is a known side effect of some immunotherapies and can lead to significant itching. Regular moisturizing with emollients is a primary management strategy for this issue.

In some cases, dermatologic side effects like itching can indicate that the immune system is being effectively stimulated. However, this is not a reliable indicator for all patients, and side effects should be managed regardless of treatment effectiveness.

If your itching is persistent, severe, or unresponsive to initial management, your oncologist may refer you to a dermatologist. A dermatologist can help exclude other skin conditions and recommend more targeted treatments.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.